PMID- 7769799
OWN - NLM
STAT- MEDLINE
DCOM- 19950706
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 25
IP  - 3
DP  - 1995 Mar
TI  - Renal and systemic hemodynamic effects of ibopamine in patients with mild to 
      moderate congestive heart failure.
PG  - 361-7
AB  - To study the hemodynamic and renal effects of the orally (p. o.) active dopamine 
      (DA) agonist ibopamine, we examined 10 patients with mild to moderate congestive 
      heart failure (CHF), who were stable while treated with digoxin and diuretics. 
      All patients were in New York Heart Association (NYHA) functional class II-III; 
      their mean age was 63 years (range 51-79 years), and mean left ventricular 
      ejection fraction (LVEF) was 28% (range 18-36%). The protocol consisted of a 
      control study-day with measurements of renal characteristics including glomerular 
      filtration rate (GFR), effective renal plasma flow (ERPF), and filtration 
      fraction (FF). One week later, systemic and renal hemodynamics were measured 
      simultaneously before and after patients received one 100-mg tablet of ibopamine. 
      Ibopamine caused a slight but significant increase in both ERPF (from 288 +/- 32 
      ml/min/1.73 m2 at baseline to 316 +/- 32 ml/min/1.73 m2 after ibopamine) and GFR 
      (from 77 +/- 8 to 85 +/- 8 ml/min/1.73 m2; both p < 0.05); FF was not affected 
      (mean value 0.26 +/- 0.02). Sodium excretion was not influenced by ibopamine, but 
      diuresis increased significantly. Cardiac output (CO) increased significantly 
      (from 4.0 +/- 0.4 L/min at baseline to a maximum of 5.0 L/min after ibopamine, p 
      < 0.05), mainly due to decreased systemic vascular resistance (SVR). Heart rate 
      (HR) and blood pressure (BP) were unchanged throughout the studies. The 
      percentage of contribution of CO to renal blood flow (RBF) was not significantly 
      affected by ibopamine.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Lieverse, A G
AU  - Lieverse AG
AD  - Department of Internal Medicine, University Hospital Groningen, The Netherlands.
FAU - van Veldhuisen, D J
AU  - van Veldhuisen DJ
FAU - Smit, A J
AU  - Smit AJ
FAU - Zijlstra, J G
AU  - Zijlstra JG
FAU - Meijer, S
AU  - Meijer S
FAU - Reitsma, W D
AU  - Reitsma WD
FAU - Lie, K I
AU  - Lie KI
FAU - Girbes, A R
AU  - Girbes AR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Vasodilator Agents)
RN  - 4964P6T9RB (Aldosterone)
RN  - 8ZCA2I2L11 (ibopamine)
RN  - 9NEZ333N27 (Sodium)
RN  - EC 3.4.23.15 (Renin)
RN  - R7339QLN1C (Deoxyepinephrine)
SB  - IM
MH  - Aged
MH  - Aldosterone/blood
MH  - Deoxyepinephrine/*analogs & derivatives/pharmacology
MH  - Female
MH  - Heart Failure/*physiopathology
MH  - Hemodynamics/*drug effects
MH  - Humans
MH  - Kidney Function Tests
MH  - Male
MH  - Middle Aged
MH  - Renal Circulation/*drug effects
MH  - Renin/blood
MH  - Sodium/blood
MH  - Vasodilator Agents/*pharmacology
EDAT- 1995/03/01 00:00
MHDA- 1995/03/01 00:01
CRDT- 1995/03/01 00:00
PHST- 1995/03/01 00:00 [pubmed]
PHST- 1995/03/01 00:01 [medline]
PHST- 1995/03/01 00:00 [entrez]
AID - 10.1097/00005344-199503000-00003 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1995 Mar;25(3):361-7. doi: 
      10.1097/00005344-199503000-00003.